Genzyme Corporation

John L Kane, Jr

Markus Metz

Andrew Scholte

Jinyu Liu

Michael Kothe

Gloria Matthews

Bradford Hirth

Shuang Qiao

John M Williams

Sharon R Nahill

Mark Czekaj

Tieu-Binh Le

Paul Erdman

Vinod Francis Patel

Bradford H Hirth

Scott F Sneddon

Hans-Peter Biemann

Fred Vinick

Frederic Vinick

Liang Ma

Claude Barberis

Linli Wei

Barret Giese

Lisa M Cuff

Jill Gregory

Patrick Wai-Kwok Shum

Marko J Pregel

Nellwyn A Hagan

Maria A Fitzgerald

Patrick Shum

John M Williams Williams

Compounds of the formula or pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising the same. The compounds are useful as colony stimulating factor-1 receptor inhibitors ('CSF-1R inhibitors').

Colony stimulating factor-1 receptor (CSF-1R) inhibitors

Tropomyosin-related kinase inhibitors (Trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune disease, defects of bone metabolism and/or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain, and pain associated with OA. Trk inhibitors are also useful for inhibiting tropomyosin-related kinase A (TrkA), tropomyosin-related kinase B (TrkB), tropomyosin-related kinase C (TrkC), and/or c-FMS (the cellular receptor for colony stimulating factor-1 (CSF-1)).

Tropomyosin-related kinase (trk) inhibitors

Tropomyosin-related kinase (Trk) inhibitors

Disclosed herein are deuterated compounds of the formula which are useful as colony stimulating factor-1 receptor inhibitors ('CSF-1R inhibitors').

Deuterated colony stimulating factor-1 receptor (CSF-1R) inhibitors

Tropomyosin-related kinase (TRK) inhibitors

Compounds of the formulas which are useful as colony stimulating factor-1 receptor inhibitors ('CSF-1R inhibitors').

The present invention provides compounds which are modulators of TNF-&#x3b1; signaling and methods of use thereof for treating a patient having a TNF-&#x3b1; mediated condition. The compounds can be represented by the following structural formulas: 

Modulators of TNF-&#x3b1; signaling

Modulators of TNF-&#x3b1;signaling

Tetrahydroisoquinoline derivatives, pharmaceutical compositions comprising them and methods of treating disease are disclosed herein. The disclosed compounds are useful in the treatment and prevention of diseases mediated by chloride channel activity and/or protein trafficking, including, but not limited to, diseases associated with impaired mucociliary clearance such as cystic fibrosis, bronchitis, emphysema, and the like.

Tetrahydroisoquinoline derivatives for treating protein trafficking diseases

The present invention provides compounds which are modulators of TNF-&#x3b1; signaling and methods of use thereof for treating a patient having a TNF-&#x3b1; mediated condition. The compounds can be represented by the following structural formulas:

Growing community of inventors

Maynard, MA, United States of America

John L Kane, Jr